Last updated on August 2010

D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia

Brief description of study

This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing connections, schizophrenic patients may derive both greater and sustained benefit from cognitive retraining.

Detailed Study Description

Patients with schizophrenia or schizoaffective disorder who are currently receiving antipsychotic medication will be randomly assigned in a double-blind manner to receive either D-serine (30 mg/kg) or placebo in addition to cognitive rehabilitation or a non-interactive placebo for 12 weeks.

Clinical Study Identifier: NCT00237809

Find a site near you

Start Over

VA Connecticut Healthcare System

West Haven, CT United States
  Connect »

Connecticut Mental Health Center

New Haven, CT United States
  Connect »